SCHEMBL1105876

SCHEMBL1105876

NC(=O)Nc1ccc(N=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 1/20 0.59
ALDH1A1 P00352 6/20 0.57
NPC1 O15118 1/20 0.57
HSD17B10 Q99714 3/20 0.56
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
GFER P55789 1/20 0.53
KIF11 P52732 6/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
PKM P14618 1/20 0.43
CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921321 0.84 PEPD (0.61) PEPDALDH1A1NPC1HSD17B10GAA
SCHEMBL5062623 0.83 PEPD (0.80) PEPDALDH1A1NPC1HSD17B10GAA
SCHEMBL11500271 0.81 PEPD (0.57) PEPDALDH1A1NPC1HSD17B10GAA
SCHEMBL13683320 0.81 ALDH1A1 (0.54) PEPDALDH1A1HSD17B10GAAMAPT
SCHEMBL8778393 0.78 MAPT (0.63) ALDH1A1NPC1HSD17B10GAAMAPT
SCHEMBL28287706 0.78 MAPT (0.68) PEPDALDH1A1NPC1GAAMAPT
SCHEMBL13784966 0.76 PEPD (0.52) PEPDALDH1A1NPC1HSD17B10GAA
SCHEMBL4572230 0.76 P2RY6 (0.53) PEPDALDH1A1NPC1HSD17B10GAA
SCHEMBL12845567 0.76 PRSS1 (0.50) PEPDALDH1A1NPC1GAAMAPT
SCHEMBL13360779 0.75 SMN1; SMN2 (0.62) ALDH1A1NPC1HSD17B10GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309543-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-13 US disclosed
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-8202861-B2 Drugs for various disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-19 US disclosed
US-8153655-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-08 US disclosed
US-7615563-B2 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2009-11-10 US disclosed
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS SCNN1G, KCNN3, KCNN2 PEPD 4409/4885ALDH1A1 2811/4885NPC1 487/4885
US-20100087479-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 PEPD 4409/4885ALDH1A1 2811/4885NPC1 487/4885
US-20060025415-A1 Compositions useful as inhibitors of voltage-gated sodium channels SCNN1G, KCNN3, KCNN2 PEPD 4409/4885ALDH1A1 2811/4885NPC1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.